caa a22 4500 39759075X CHVBK 20180308164937.0 cr unu---uuuuu 161202e199605 xx s 000 0 eng 10.1093/jac/37.suppl_A.135 doi (NATIONALLICENCE)oxford-10.1093/jac/37.suppl_A.135 Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection [Elektronische Daten] [Kurt G. Naber, F. Di Silveriob, A. Geddes, J. Guibert] A total of 686 adult patients with complicated urinary tract infections were enrolled in a double-blind, randomised, multicentre study to compare sparfloxacin (200 mg loading dose on day 1 followed by 100 mg daily) with ciprofloxacin (500 mg orally twice daily) for 10 to 14 days. Urinary tract infection was defined as pyuria and bacteriuria (cfu ≥ 105/mL). Evaluations were performed at four time-points. The clinical efficacy of the two antibacterial agents was equivalent at the end of treatment: clinical cure in 88.6% of the intent-to-treat population and 87.3% in the evaluable population treated with sparfloxacin compared to 85.4% and 84.8% of the intent-to-treat and evaluable populations, respectively, treated with ciprofloxacin. The clinical results were also equivalent at follow-up. The bacteriological efficacy of the two agents was not equivalent. At the end of treatment, bacteriological cure was observed in 72.6% of the intent-to-treat and 72.1% of the evaluable populations treated with sparfloxacin and in 81.4% and 80.8% of the intent-to-treat and evaluable populations, respectively, treated with ciprofloxacin. The difference was primarily because of a higher number of persisting pathogens, which included Enterobacteriaceae other than Escherichia coli, Pseudomonas aeruginosa and enterococci, which exhibited moderate susceptibility to sparfloxacin. Tolerability was similar in the two treatment groups. © 1996 The British Society for Antimicrobial Chemotherapy Articles nationallicence Naber Kurt G. Urologic Clinic, Elisabeth Hospital Straubing, Germany aut Di Silveriob F. Clinica Urologica, Universita Degli Studi Rome, Italy aut Geddes A. Department of Infectious Diseases, Birmingham Heartlands Hospital Birmingham, UK aut Guibert J. Service de Microbiologie Medicale, Hospital Saint-Joseph Paris, France aut Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-05), 135-144 0305-7453 37<135 1996 37 jac https://doi.org/10.1093/jac/37.suppl_A.135 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.suppl_A.135 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Naber Kurt G. Urologic Clinic, Elisabeth Hospital Straubing, Germany aut NATIONALLICENCE 700 1- Di Silveriob F. Clinica Urologica, Universita Degli Studi Rome, Italy aut NATIONALLICENCE 700 1- Geddes A. Department of Infectious Diseases, Birmingham Heartlands Hospital Birmingham, UK aut NATIONALLICENCE 700 1- Guibert J. Service de Microbiologie Medicale, Hospital Saint-Joseph Paris, France aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-05), 135-144 0305-7453 37<135 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford